Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Here’s Why

Bavarian Nordic (OTCMKTS:BVNRY) shares saw unusually-strong trading volume on Friday . Approximately 4,000 shares changed hands during trading, an increase of 18% from the previous session’s volume of 3,400 shares.The stock last traded at $9.4260 and had previously closed at $9.3750.

Bavarian Nordic Trading Up 1.3%

The firm has a 50-day moving average of $9.90 and a 200-day moving average of $9.93. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of 12.46 and a beta of 1.19.

Bavarian Nordic (OTCMKTS:BVNRY) last released its earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. Bavarian Nordic had a return on equity of 9.37% and a net margin of 19.74%.The firm had revenue of $165.70 million for the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.